OMass Therapeutics, a biotechnology company harnessing native mass spectrometry and other biophysical technologies to drive drug discovery in high definition. Using this technology allows OMass to interrogate not just the target but how it interacts with its native ecosystem, separate from the confounding complexity of the cell. The company was established in 2016 as a spin out from the University of Oxford, Department of Chemistry and backed by Syncona and Oxford Science Enterprises, having closed a $60m Series A funding round. Currently, we are advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, targeting solute carriers, complex-bound proteins and GPCRs.
OMass
